A Double-Blinded Positive Control Study Comparing the Relative Efficacy of 2.5% Polyacrylamide Hydrogel (PAAG) Against Triamcinolone Acetonide (TA) And Sodium Hyaluronate (HA) in the Management of Middle Carpal Joint Lameness in Racing Thoroughbreds.

Autor: de Clifford LT; Matamata Veterinary Services Limited, Matamata, New Zealand., Lowe JN; Innovative Medical Solutions Limited, Cambridge, New Zealand., McKellar CD; AK & K Equine Services, Miners Rest, Victoria, Australia., McGowan C; Equine Clinical Science, University of Liverpool, Leahurst, United Kingdom., David F; Equine Veterinary Medical Center, Member of Qatar Foundation, Al Rayyan, Doha, Qatar; College of Health & Life Science, Hamad Bin Khalifa University, Member of Qatar Foundation, Education city, Doha, Qatar. Electronic address: fdavid@qf.org.qa.
Jazyk: angličtina
Zdroj: Journal of equine veterinary science [J Equine Vet Sci] 2021 Dec; Vol. 107, pp. 103780. Date of Electronic Publication: 2021 Sep 24.
DOI: 10.1016/j.jevs.2021.103780
Abstrakt: The purpose of this prospective double-blinded positive control study was to compare the efficacy of 2.5% polyacrylamide hydrogel (2.5% PAAG) in the management of middle carpal joint lameness in Thoroughbreds against treatments of triamcinolone acetonide (TA) or sodium hyaluronate (HA). A total of 31 flat-racing Thoroughbreds with lameness (grade 1-3/5) localized to the carpus by intra-articular analgesia were selected. Following a radiological assessment of the carpi confirming the absence of fragment/fracture, the horses were randomly assigned for intra-articular treatment with either 2 ml of 2.5% PAAG, 12 mg TA or 20 mg HA (followed by two further intravenous treatments of 40 mg, at weekly intervals in the HA group only), by a treating veterinarian. All horses were rested for 48 hours post-treatment and then re-entered an unaltered training regimen. Subsequent examinations at 2, 4, and 6 weeks were performed by a blinded examining veterinarian for all groups, while horses treated with 2.5% PAAG were monitored for 12 weeks for recurrence of lameness. Significantly more joints treated with 2.5% PAAG were lame free (83%) at 6 weeks compared to TA (27%; P = .007) and to HA (40%; P = .04). There was no significant difference between TA and HA groups at any time. All the joints treated within 2.5% PAAG that were lame free at 6 weeks (10/12) were still lame-free at 12 weeks. In conclusion, treatment with 2.5% PAAG led to statistically superior results compared to TA and HA in the management of selected middle carpal joint lameness in flat-racing Thoroughbreds, with therapeutic effects persisting up to 12 weeks.
(Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: